MX2013000001A - Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. - Google Patents

Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.

Info

Publication number
MX2013000001A
MX2013000001A MX2013000001A MX2013000001A MX2013000001A MX 2013000001 A MX2013000001 A MX 2013000001A MX 2013000001 A MX2013000001 A MX 2013000001A MX 2013000001 A MX2013000001 A MX 2013000001A MX 2013000001 A MX2013000001 A MX 2013000001A
Authority
MX
Mexico
Prior art keywords
sustained release
release phase
pharmaceutical composition
dapoxetine
present
Prior art date
Application number
MX2013000001A
Other languages
English (en)
Inventor
Lee Chang-Kyoo
Park Sang-Geun
Original Assignee
Navipharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Navipharm Co Ltd filed Critical Navipharm Co Ltd
Publication of MX2013000001A publication Critical patent/MX2013000001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se relaciona con una composición farmacéutica de liberación prolongada y acción retardada para la administración oral, la cual comprende una fase de liberación inmediata y una fase de liberación sostenida prolongada, donde la fase de liberación inmediata y la fase de liberación sostenida prolongada comprenden respectivamente Dapoxetina en ellas como un ingrediente activo. La composición farmacéutica de la presente invención comprende Dapoxetina, la cual es un agente para el tratamiento de la eyaculación prematura, en ambas de la fase de liberación inmediata y la fase de liberación sostenida prolongada de la misma, para exhibir por lo tanto inmediatamente la efectividad de la composición farmacéutica de la presente invención para permitir a un paciente lograr satisfacción sexual durante la etapa inicial de administración, así como para reducir los efectos laterales por medio de la liberación prolongada y de acción retardada de la fase de liberación sostenida prolongada durante la etapa inicial de la administración y permitir una absorción continua in vivo de Dapoxetinas, para prolongar por lo tanto la duración de la efectividad de la composición farmacéutica de la presente invención. Además, pueden ser agregados agentes para tratar la disfunción eréctil, como el Sildenafil, Tadalafil o similares a la fase de liberación inmediata para permitir la coincidencia de la duración de la efectividad de un agente de tratamiento para la eyaculación prematura y agentes de tratamiento de la disfunción eréctil, aún cuando exista una diferencia en la vida media entre los dos tipos de agentes de tratamiento, maximizando de este modo la satisfacción del paciente.
MX2013000001A 2010-07-06 2011-07-05 Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. MX2013000001A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100064988 2010-07-06
PCT/KR2011/004919 WO2012005500A2 (ko) 2010-07-06 2011-07-05 다폭세틴을 포함하는 시간차 서방출 경구투여형 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2013000001A true MX2013000001A (es) 2013-05-01

Family

ID=45441646

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013000001A MX2013000001A (es) 2010-07-06 2011-07-05 Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.

Country Status (9)

Country Link
US (1) US20130095180A1 (es)
EP (1) EP2591773A4 (es)
JP (1) JP2013530220A (es)
KR (1) KR101465077B1 (es)
CN (1) CN102958513A (es)
CA (1) CA2804341A1 (es)
MX (1) MX2013000001A (es)
RU (1) RU2012157127A (es)
WO (1) WO2012005500A2 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine
KR101230178B1 (ko) 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
CN103100085A (zh) * 2011-11-09 2013-05-15 上海兰蒂斯生物医药科技有限公司 一种药物组合物
WO2013180675A1 (en) * 2012-05-28 2013-12-05 Mahmut Bilgic Tablet formulation comprising dapoxetine
CN103127023B (zh) * 2013-03-01 2014-08-27 河北天成药业股份有限公司 一种盐酸度洛西汀肠溶片及其制备方法
CN103340869B (zh) * 2013-06-28 2015-04-01 王立强 用于阳痿早泄的组合物
CN105987971B (zh) * 2015-02-12 2020-07-14 重庆华邦制药有限公司 盐酸达泊西汀中间体sm1及相关杂质的分离与测定方法
US20160297747A1 (en) 2015-04-08 2016-10-13 Invista North America S.A.R.L. Materials and methods for the selective recovery of monovalent products from aqueous solutions using continuous ion exchange
US10343084B2 (en) 2015-04-10 2019-07-09 Invista North America S.A.R.L. Process for separation of diamines and/or omega-aminoacids from a feed mixture
WO2017017511A1 (en) * 2015-07-28 2017-02-02 Kameel Selim Modified release formulation for treating premature ejaculation
CN106389360A (zh) * 2015-07-31 2017-02-15 重庆华邦制药有限公司 盐酸达泊西汀直压片及其制备方法
CN106511312A (zh) * 2015-09-11 2017-03-22 扬子江药业集团江苏紫龙药业有限公司 一种复方西地那非达泊西汀缓释胶囊及其制备方法
CN107536821A (zh) * 2016-06-29 2018-01-05 康普药业股份有限公司 一种盐酸达泊西汀缓释制剂
CN107536817A (zh) * 2016-06-29 2018-01-05 康普药业股份有限公司 一种盐酸达泊西汀药物组合物
TR201715231A2 (tr) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi Dapokseti̇n ve fosfodi̇esteraz ti̇p-5 i̇nhi̇bi̇törü i̇çeren farmasöti̇k kombi̇nasyon
CN108033960A (zh) * 2018-01-23 2018-05-15 中国药科大学 一种他达拉非的共无定形物
CN111407734A (zh) * 2019-01-05 2020-07-14 厦门赛诺邦格生物科技股份有限公司 一种阳痿早泄治疗药物的固体制剂
EP4079297A4 (en) * 2019-12-19 2023-03-08 Celltrion, Inc. PHARMACEUTICAL FORMULATION COMPRISING CIBENZOLINE OR A SALT THEREOF
CN113456606A (zh) * 2020-03-30 2021-10-01 北京新领先医药科技发展有限公司 一种盐酸达泊西汀片制备方法
CN113143879A (zh) * 2021-05-07 2021-07-23 苏州康恒研新药物技术有限公司 一种盐酸达泊西汀缓释片的制备方法
CN115887462A (zh) * 2021-09-30 2023-04-04 上海汇伦医药股份有限公司 一种口服药物组合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
KR20010016952A (ko) 1999-08-05 2001-03-05 박인규 임피던스가 보상된 전력 전송 회로
ATE318135T1 (de) 1999-09-03 2006-03-15 Apbi Holdings Llc Verwendung von dapoxetin, a selektiver serotonin- aufnahme inhibitor mit schnellem wirkungseintritt,zur behandlung von sexueller dysfunction
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
US8153159B2 (en) * 2003-09-18 2012-04-10 Cephalon, Inc. Modafinil modified release pharmaceutical compositions
AT500144A1 (de) 2004-03-05 2005-11-15 Sanochemia Pharmazeutika Ag Tolperison enthaltende, pharmazeutische zubereitung mit steuerbarer wirkstofffreisetzung zur oralen verabreichung
CA2612917A1 (en) * 2005-06-23 2007-01-04 Schering Corporation Rapidly absorbing oral formulations of pde5 inhibitors
US20090118211A1 (en) * 2005-06-27 2009-05-07 Daniel Drai Compositions and Methods for Enhancement of Sexual Function
EP2167048B1 (en) * 2007-05-30 2016-10-26 Wockhardt Limited A novel tablet dosage form
IN2008MU01128A (es) * 2008-05-27 2009-12-11 Ajanta Pharma Ltd
KR20100045344A (ko) * 2008-10-23 2010-05-03 한올바이오파마주식회사 방출성이 제어된 베타 아드레날린 차단제와 ＨＭＧ-ＣｏＡ 환원 효소 억제제의 신규 복합 조성물
WO2010103544A2 (en) 2009-03-09 2010-09-16 Dinesh Shantilal Patel A novel sustained release composition of compounds selected from the class of centrally acting muscle relaxants
EP2316435A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical compositions of PDE-5 inhibitors and dapoxetine

Also Published As

Publication number Publication date
US20130095180A1 (en) 2013-04-18
CA2804341A1 (en) 2012-01-12
JP2013530220A (ja) 2013-07-25
WO2012005500A3 (ko) 2012-05-03
CN102958513A (zh) 2013-03-06
WO2012005500A2 (ko) 2012-01-12
RU2012157127A (ru) 2014-08-20
KR20130032316A (ko) 2013-04-01
EP2591773A2 (en) 2013-05-15
EP2591773A4 (en) 2014-11-26
KR101465077B1 (ko) 2014-11-26

Similar Documents

Publication Publication Date Title
MX2013000001A (es) Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral.
WO2008131057A3 (en) Sustained release formulations of opioid and nonopioid analgesics
WO2008131056A3 (en) Sustained release monoeximic formulations of opioid and nonopioid analgesics
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MXPA06013133A (es) Formulaciones farmaceuticas y usos de las mismas en el tratamiento de la disfuncion sexual femenina.
PL1891038T3 (pl) Podstawione n-arylopirolidyny jako selektywne modulatory receptora androgenowego
MY143795A (en) Tetrahydropyridoindole derivatives
DOP2013000245A (es) Preparacion de gadobutrol de alta pureza
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
GB2491327A (en) Delayed prolonged drug delivery
GB2491775A (en) Pulsatile drug release
PL2210588T3 (pl) Kompozycje pianotwórcze do leczenia skóry ludzkiej zasadniczo niezawierające aktywnych składników farmaceutycznych
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
WO2011118976A3 (en) Pharmaceutical composition for the prevention or the treatment of non-alcoholic fatty liver disease and the method for prevention or treatment of non-alcoholic fatty liver disease using the same
RU2009120990A (ru) Применение тестостерона и агониста 5-нт1а для лечения сексуальной дисфункции
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
MX2009011900A (es) Curacion de herida diabetica.
MX2009005798A (es) Recuperacion de apoplejia.
MX369117B (es) Antagonistas del receptor ep4 para el tratamiento de cancer.
EA201071352A1 (ru) Трициклические азотсодержащие соединения и их применение в качестве бактерицидных средств
WO2008051527A3 (en) Sustained release of agents for localized pain management
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.

Legal Events

Date Code Title Description
HH Correction or change in general
HH Correction or change in general
FA Abandonment or withdrawal